Grifols (NASDAQ:GRFS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on the stock. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $10.00.

Grifols Stock Performance

Grifols stock opened at $7.36 on Friday. The company has a market cap of $5.01 billion, a PE ratio of 38.74, a P/E/G ratio of 0.27 and a beta of 0.67. The company has a fifty day moving average price of $7.75 and a two-hundred day moving average price of $7.81. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. Grifols has a 12 month low of $6.96 and a 12 month high of $10.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Brandes Investment Partners LP raised its holdings in shares of Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after buying an additional 1,838,727 shares during the last quarter. Armistice Capital LLC increased its position in Grifols by 23.8% in the 4th quarter. Armistice Capital LLC now owns 2,768,000 shares of the biotechnology company’s stock valued at $25,881,000 after acquiring an additional 532,000 shares during the period. Norges Bank acquired a new stake in Grifols in the 4th quarter valued at approximately $18,139,000. Flat Footed LLC raised its stake in Grifols by 26.5% during the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after acquiring an additional 287,867 shares in the last quarter. Finally, Tidal Investments LLC boosted its position in Grifols by 9.8% during the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after acquiring an additional 109,612 shares during the period.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.